107 related articles for article (PubMed ID: 18067016)
1. Biologic predictors in follicular lymphoma: importance of markers of immune response.
Kelley T; Beck R; Absi A; Jin T; Pohlman B; Hsi E
Leuk Lymphoma; 2007 Dec; 48(12):2403-11. PubMed ID: 18067016
[TBL] [Abstract][Full Text] [Related]
2. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
Richendollar BG; Pohlman B; Elson P; Hsi ED
Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
[TBL] [Abstract][Full Text] [Related]
3. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
Canioni D; Salles G; Mounier N; Brousse N; Keuppens M; Morchhauser F; Lamy T; Sonet A; Rousselet MC; Foussard C; Xerri L
J Clin Oncol; 2008 Jan; 26(3):440-6. PubMed ID: 18086798
[TBL] [Abstract][Full Text] [Related]
4. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
Sweetenham JW; Goldman B; LeBlanc ML; Cook JR; Tubbs RR; Press OW; Maloney DG; Fisher RI; Rimsza LM; Braziel RM; Hsi ED
Ann Oncol; 2010 Jun; 21(6):1196-1202. PubMed ID: 19875761
[TBL] [Abstract][Full Text] [Related]
6. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).
Farinha P; Masoudi H; Skinnider BF; Shumansky K; Spinelli JJ; Gill K; Klasa R; Voss N; Connors JM; Gascoyne RD
Blood; 2005 Sep; 106(6):2169-74. PubMed ID: 15933054
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
Cánovas A; Alonso JJ; Barreiro G; Aguirre C
Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
[TBL] [Abstract][Full Text] [Related]
8. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
10. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Nam SJ; Go H; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2014 Nov; 55(11):2466-76. PubMed ID: 24397616
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of PU.1 in follicular lymphoma.
Torlakovic EE; Bilalovic N; Golouh R; Zidar A; Angel S
J Pathol; 2006 Jul; 209(3):352-9. PubMed ID: 16639693
[TBL] [Abstract][Full Text] [Related]
12. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
Wahlin BE; Aggarwal M; Montes-Moreno S; Gonzalez LF; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
Clin Cancer Res; 2010 Jan; 16(2):637-50. PubMed ID: 20068089
[TBL] [Abstract][Full Text] [Related]
13. Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K
Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
Mozessohn L; Cheung MC; Crump M; Buckstein R; Berinstein N; Imrie K; Kuruvilla J; Piliotis E; Kukreti V
Leuk Lymphoma; 2014 Nov; 55(11):2502-7. PubMed ID: 24450580
[TBL] [Abstract][Full Text] [Related]
15. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.
Farinha P; Al-Tourah A; Gill K; Klasa R; Connors JM; Gascoyne RD
Blood; 2010 Jan; 115(2):289-95. PubMed ID: 19901260
[TBL] [Abstract][Full Text] [Related]
16. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
Carreras J; Lopez-Guillermo A; Fox BC; Colomo L; Martinez A; Roncador G; Montserrat E; Campo E; Banham AH
Blood; 2006 Nov; 108(9):2957-64. PubMed ID: 16825494
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Cheong JW; Kim YR; Lee JY; Jang JE; Kim Y; Min YH; Kim JS
Ann Hematol; 2017 Jul; 96(7):1163-1173. PubMed ID: 28508176
[TBL] [Abstract][Full Text] [Related]
19. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
20. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]